PepGen (NASDAQ:PEPG) Given New $5.00 Price Target at Wedbush

PepGen (NASDAQ:PEPG) had its price target lowered by Wedbush from $9.00 to $5.00 in a report published on Tuesday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other research analysts also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of PepGen in a research report on Thursday, January 22nd. Guggenheim increased their price target on PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Finally, Oppenheimer assumed coverage on PepGen in a research note on Wednesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.80.

PepGen Trading Down 57.4%

PEPG opened at $1.80 on Tuesday. PepGen has a 12-month low of $0.88 and a 12-month high of $7.80. The firm has a 50 day moving average of $5.51 and a two-hundred day moving average of $5.22. The firm has a market capitalization of $124.61 million, a PE ratio of -0.75 and a beta of 1.87.

PepGen (NASDAQ:PEPG) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.13. As a group, analysts predict that PepGen will post -2.73 EPS for the current fiscal year.

Hedge Funds Weigh In On PepGen

Several institutional investors have recently made changes to their positions in PEPG. RA Capital Management L.P. boosted its holdings in PepGen by 87.7% during the third quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock worth $92,698,000 after buying an additional 9,375,000 shares in the last quarter. Commodore Capital LP purchased a new position in PepGen in the third quarter valued at $10,891,000. Vivo Capital LLC acquired a new position in shares of PepGen in the third quarter worth about $10,742,000. Viking Global Investors LP raised its position in shares of PepGen by 134.9% in the third quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock worth $16,089,000 after acquiring an additional 2,000,000 shares during the period. Finally, Nantahala Capital Management LLC purchased a new stake in shares of PepGen during the 4th quarter worth about $10,072,000. 58.01% of the stock is owned by hedge funds and other institutional investors.

More PepGen News

Here are the key news stories impacting PepGen this week:

• Positive Sentiment: PepGen reported favorable safety, splicing and vHOT biomarker data from the 5 mg/kg MAD cohort and framed the totality of results as encouraging — the company says higher doses could address efficacy questions. PepGen Announces Topline Results (BusinessWire)
• Positive Sentiment: A Seeking Alpha transcript of management’s comments on the lowest‑dose cohort reiterates the favorable safety and biomarker findings, providing more color for investors watching next steps and dose escalation plans. PEPG Discusses Topline Results (Seeking Alpha)
• Neutral Sentiment: Wedbush cut its price target from $9 to $5 but kept an Outperform rating — an analyst reset that signals calibrated optimism (still bullish on upside) despite the new data. Wedbush Lowers PT (Benzinga)
• Neutral Sentiment: Trading was temporarily halted around the release for “News pending,” which is typical for material clinical updates but contributed to rapid price moves when trading resumed.
• Negative Sentiment: Market reaction: multiple outlets reported steep sell‑offs after the mixed FREEDOM2 readout — investors appear to have focused on limited efficacy signal at the lowest dose and uncertainty around timing/impact of higher‑dose data. PepGen Plunges On Mixed Phase 2 Data (Seeking Alpha)
• Negative Sentiment: Coverage emphasized a sharp share price decline and investor concern about commercial prospects if efficacy requires higher dosing; this accelerated selling pressure. PepGen Loses Half of Share Price (BioSpace)
• Negative Sentiment: Two law firms (Pomerantz, Johnson Fistel) announced investor investigations into PepGen, a development that typically increases short‑term downside risk and legal overhang. Pomerantz Investigation (GlobeNewswire) Johnson Fistel Notice (GlobeNewswire)

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).